These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 30373998)

  • 61. Hypocalcaemia in patients with metastatic bone disease treated with denosumab.
    Body JJ; Bone HG; de Boer RH; Stopeck A; Van Poznak C; Damião R; Fizazi K; Henry DH; Ibrahim T; Lipton A; Saad F; Shore N; Takano T; Shaywitz AJ; Wang H; Bracco OL; Braun A; Kostenuik PJ
    Eur J Cancer; 2015 Sep; 51(13):1812-21. PubMed ID: 26093811
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Cost-effectiveness of denosumab in preventing skeletal-related events in bone metastases.
    Giuliani J
    J Oncol Pharm Pract; 2021 Dec; 27(8):2000-2003. PubMed ID: 34558357
    [No Abstract]   [Full Text] [Related]  

  • 63. Bone targeted therapy for preventing skeletal-related events in metastatic breast cancer.
    Irelli A; Cocciolone V; Cannita K; Zugaro L; Di Staso M; Lanfiuti Baldi P; Paradisi S; Sidoni T; Ricevuto E; Ficorella C
    Bone; 2016 Jun; 87():169-75. PubMed ID: 27091227
    [TBL] [Abstract][Full Text] [Related]  

  • 64. How do skeletal morbidity rate and special toxicities affect 12-week versus 4-week schedule zoledronic acid efficacy? A systematic review and a meta-analysis of randomized trials.
    Santini D; Galvano A; Pantano F; Incorvaia L; Rizzo S; Vincenzi B; Castellana L; Giuliana G; Guadagni F; Toia F; Tonini G; Russo A; Badalamenti G; Bazan V
    Crit Rev Oncol Hematol; 2019 Oct; 142():68-75. PubMed ID: 31377434
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Targeting Osteocytes to Attenuate Early Breast Cancer Bone Metastasis by Theranostic Upconversion Nanoparticles with Responsive Plumbagin Release.
    Qiao H; Cui Z; Yang S; Ji D; Wang Y; Yang Y; Han X; Fan Q; Qin A; Wang T; He XP; Bu W; Tang T
    ACS Nano; 2017 Jul; 11(7):7259-7273. PubMed ID: 28692257
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Treatment and pattern of bone metastases in 1094 patients with advanced breast cancer - Results from the prospective German Tumour Registry Breast Cancer cohort study.
    Schröder J; Fietz T; Köhler A; Petersen V; Tesch H; Spring L; Fleitz A; Jänicke M; Marschner N;
    Eur J Cancer; 2017 Jul; 79():139-148. PubMed ID: 28494404
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Denosumab: benefits of RANK ligand inhibition in cancer patients.
    Lipton A; Jacobs I
    Curr Opin Support Palliat Care; 2011 Sep; 5(3):258-64. PubMed ID: 21826000
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Bone Health and Bone-targeted Therapies for Prostate Cancer: a Programme in Evidence-based Care - Cancer Care Ontario Clinical Practice Guideline.
    Alibhai SMH; Zukotynski K; Walker-Dilks C; Emmenegger U; Finelli A; Morgan SC; Hotte SJ; Winquist E;
    Clin Oncol (R Coll Radiol); 2017 Jun; 29(6):348-355. PubMed ID: 28169118
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Harnessing the potential of therapeutic agents to safeguard bone health in prostate cancer.
    Miller K; Steger GG; Niepel D; Lüftner D
    Prostate Cancer Prostatic Dis; 2018 Nov; 21(4):461-472. PubMed ID: 29988100
    [TBL] [Abstract][Full Text] [Related]  

  • 70. New anti-resorptives and antibody mediated anti-resorptive therapy.
    Farrier AJ; Sanchez Franco LC; Shoaib A; Gulati V; Johnson N; Uzoigwe CE; Choudhury MZ
    Bone Joint J; 2016 Feb; 98-B(2):160-5. PubMed ID: 26850419
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Progress in the treatment of bone metastases in cancer patients.
    Mackiewicz-Wysocka M; Pankowska M; Wysocki PJ
    Expert Opin Investig Drugs; 2012 Jun; 21(6):785-95. PubMed ID: 22500564
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Cost-effectiveness of denosumab as a bone protective agent for patients with castration resistant prostate cancer.
    Dellis A; Papatsoris A
    Expert Rev Pharmacoecon Outcomes Res; 2016; 16(1):5-10. PubMed ID: 26588857
    [TBL] [Abstract][Full Text] [Related]  

  • 73. THERAPY OF ENDOCRINE DISEASE: Denosumab vs bisphosphonates for the treatment of postmenopausal osteoporosis.
    Anastasilakis AD; Polyzos SA; Makras P
    Eur J Endocrinol; 2018 Jul; 179(1):R31-R45. PubMed ID: 29691303
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Pharmacotherapy of bone metastases in breast cancer patients.
    Petrut B; Simmons C; Broom R; Trinkaus M; Clemons M
    Expert Opin Pharmacother; 2008 Apr; 9(6):937-45. PubMed ID: 18377337
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Cost-effectiveness of denosumab versus zoledronic acid in the management of skeletal metastases secondary to breast cancer.
    Snedecor SJ; Carter JA; Kaura S; Botteman MF
    Clin Ther; 2012 Jun; 34(6):1334-49. PubMed ID: 22578308
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Effect of Denosumab on Falls, Muscle Strength, and Function in Community-Dwelling Older Adults.
    Phu S; Bani Hassan E; Vogrin S; Kirk B; Duque G
    J Am Geriatr Soc; 2019 Dec; 67(12):2660-2661. PubMed ID: 31483858
    [No Abstract]   [Full Text] [Related]  

  • 77. Analysis of denosumab on skeletal-related events in patients with advanced breast cancer.
    Bink KF
    Clin J Oncol Nurs; 2015 Oct; 19(5):E108-14. PubMed ID: 26414586
    [TBL] [Abstract][Full Text] [Related]  

  • 78. [The treatment for cancer with bone metastases -whether to use zoledoronate or denosumab for bone metastases-].
    Kohno N
    Clin Calcium; 2014 Aug; 24(8):1229-36. PubMed ID: 25065876
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Effect of Bisphosphonates, Denosumab, and Radioisotopes on Bone Pain and Quality of Life in Patients with Non-Small Cell Lung Cancer and Bone Metastases: A Systematic Review.
    Hendriks LE; Hermans BC; van den Beuken-van Everdingen MH; Hochstenbag MM; Dingemans AM
    J Thorac Oncol; 2016 Feb; 11(2):155-73. PubMed ID: 26718881
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Spanish Menopause Society position statement: Use of denosumab in postmenopausal women.
    Cano A; Silvan JM; Estévez A; Baró F; Villero J; Quereda F; Ferrer J; Mendoza N; Sánchez-Borrego R;
    Maturitas; 2014 Sep; 79(1):117-21. PubMed ID: 25042873
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.